Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of rs1219648 in FGFR2 and rs1042522 in TP53 with Premenopausal Breast Cancer in an Iranian Azeri Population

  • Saadatian, Zahra (International Branch of Tabriz University of Medical Sciences (Aras)) ;
  • Gharesouran, Jalal (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Ghojazadeh, Morteza (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Ghohari-Lasaki, Sahar (Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences) ;
  • Tarkesh-Esfahani, Najime (Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences) ;
  • Ardebili, Seyyed Mojtaba Mohaddes (International Branch of Tabriz University of Medical Sciences (Aras))
  • Published : 2014.10.11
Download PDF
⟨ Previous Next ⟩

Abstract

Breast cancer is the most common cancer among women in the world. In Iran, the incidence of breast cancer is on the increase. We here studied the association of rs1219648 in FGFR2 and rs1042522 in TP53 and their interaction in development of early onset sporadic breast cancer in Iranian Azeri population to evaluate epistatic effects on the risk of mammary neoplasia. We genotyped the two polymorphisms in 100 women with early onset breast cancer and 100 healthy women by PCR-RFLP. Allele frequency differences were tested using $chi^2$-test with 95% confident intervals. Our results indicated a statistically significant association (p<0.05) between rs1219648, but not rs1042522, and risk of breast cancer. We also found that the combination of FGFR2 major genotype and TP53 hetero genotype had protective effects against breast cancer, while the hetero allele of FGFR2 in combination with the minor genotype of TP53 was associated with a high risk. This study revealed an important crosstalk between two polymorphisms in FGFR2 and TP53 in development of breast cancer. These candidates risk variants should be further evaluated in studies with a larger sample size.

Keywords

References

  1. Al-Qasem A, Toulimat M, Tulbah A, et al (2012). The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett, 3, 875-8.
  2. Ayoub N, Lucas C, Kaddoumi A (2011). Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev, 12, 1127-40.
  3. Buyru N, Tigli H, Dalay N (2003). P53 codon 72 polymorphism in breast cancer. Oncol Rep, 10, 711-4.
  4. Cherdyntseva NV, Denisov EV, Litviakov NV, et al (2012). Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis. DNA Cell Biol, 31, 306-16. https://doi.org/10.1089/dna.2011.1351
  5. Denisov EV, Cherdyntseva NV, Litviakov NV, et al (2012). TP53 gene polymorphisms in cancer risk: the modulating effect of ageing, ethnicity and TP53 somatic abnormalities. In 'Tumor Suppressor Genes', Eds Intech, 79-110.
  6. Doosti A, Ghasemi-Dehkordi P, Davoudi N (2011). p53 codon72 polymorphism associated with breast cancer in Iranian patients. African J Pharmacy Pharmacol, 5, 1278-81. https://doi.org/10.5897/AJPP10.394
  7. Fu F, Wang C, Huang M, et al (2012). Polymorphisms in second intron of the FGFR2 gene are associated with the risk of early-onset breast cancer in Chinese Han women. Tohoku J Exp Med, 226, 221-9. https://doi.org/10.1620/tjem.226.221
  8. Garner I (2000). The Nucleic Acid Protocols Handbook. In Eds Humana Press, 3-7.
  9. Han W, Woo JH, Yu JH, et al (2011). Common genetic variants associated with breast cancer in Korean women and differential susceptibility according to intrinsic subtype. Cancer Epidemiol Biomarkers Prev, 20, 793-8. https://doi.org/10.1158/1055-9965.EPI-10-1282
  10. He XF, Su J, Zhang Y, et al (2011). Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat, 130, 517-29. https://doi.org/10.1007/s10549-011-1583-2
  11. Hosokawa K, Aharoni D, Dantes A, et al (1998). Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. Endocrinology, 139, 4688-700.
  12. Hu Z, Li X, Yuan R, et al (2010). Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat, 120, 705-14. https://doi.org/10.1007/s10549-009-0488-9
  13. Hunter DJ, Kraft P, Jacobs KB, et al (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet, 39, 870-4. https://doi.org/10.1038/ng2075
  14. Jia C, Cai Y, Ma Y, et al (2010). Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer. Breast Cancer Res Treat, 124, 521-8. https://doi.org/10.1007/s10549-010-0872-5
  15. Katoh M (2008). Cancer genomics and genetics of FGFR2 (Review). Int J Oncol, 33, 233-7.
  16. Khadang B, Fattahi MJ, Talei A, et al (2007). Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet, 173, 38-42. https://doi.org/10.1016/j.cancergencyto.2006.09.010
  17. Khan MH, Rashid H, Mansoor Q, et al (2014). Association of the rs1042522 polymorphism with increased risk of prostate adenocarcinoma in the Pakistani population and its HuGE review. Asian Pac J Cancer Prev, 15, 3973-80. https://doi.org/10.7314/APJCP.2014.15.9.3973
  18. Li X, Dumont P, Della Pietra A, et al (2005). The codon 47 polymorphism in p53 is functionally significant. J Biol Chem, 280, 24245-51. https://doi.org/10.1074/jbc.M414637200
  19. Liang J, Chen P, Hu Z, et al (2008). Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis, 29, 2341-6. https://doi.org/10.1093/carcin/bgn235
  20. Liu CL, Hu XP, Guo WD, et al (2013). Case-control study on the fibroblast growth factor receptor 2 gene polymorphisms associated with breast cancer in Chinese Han women. J Breast Cancer, 16, 366-71. https://doi.org/10.4048/jbc.2013.16.4.366
  21. Long J, Zhang B, Signorello LB, et al (2013). Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS One, 8, 58350. https://doi.org/10.1371/journal.pone.0058350
  22. Marian C, Ochs-Balcom HM, Nie J, et al (2011). FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer, 129, 702-12. https://doi.org/10.1002/ijc.25686
  23. Ota S, Zhou ZQ, Link JM, et al (2009). The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet, 18, 2609-21. https://doi.org/10.1093/hmg/ddp195
  24. Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92. https://doi.org/10.1006/mcbr.2000.0241
  25. Pouladi N, Kouhsari SM, Feizi MH, et al (2014). Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev, 15, 2631-4. https://doi.org/10.7314/APJCP.2014.15.6.2631
  26. Prentice RL, Huang Y, Hinds DA, et al (2009). Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 18, 3079-85. https://doi.org/10.1158/1055-9965.EPI-09-0611
  27. Rahimzadeh M, Baghestani AR, Gohari MR, et al (2014). Estimation of the cure rate in Iranian breast cancer patients. Asian Pac J Cancer Prev, 15, 4839-42. https://doi.org/10.7314/APJCP.2014.15.12.4839
  28. Rai V (2014). The methylenetetrahydrofolate reductase C677T polymorphism and breast cancer risk in asian populations. Asian Pac J Cancer Prev, 15, 5853-60. https://doi.org/10.7314/APJCP.2014.15.14.5853
  29. Raskin L, Pinchev M, Arad C, et al (2008). FGFR2 is a breast cancer susceptibility gene in jewish and arab israeli populations. Cancer Epidemiol Biomarkers Prev, 17, 1060-5. https://doi.org/10.1158/1055-9965.EPI-08-0018
  30. Shaulian E, Resnitzky D, Shifman O, et al (1997). Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene, 15, 2717-25. https://doi.org/10.1038/sj.onc.1201453
  31. Singh V, Rastogi N, Mathur N, et al (2008). Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol, 18, 48-57. https://doi.org/10.1016/j.annepidem.2007.06.006
  32. Sun C, Olopade OI, Di Rienzo A (2010). rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet, 197, 193-4. https://doi.org/10.1016/j.cancergencyto.2009.11.006
  33. Suspitsin EN, Buslov KG, Grigoriev MY, et al (2003). Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer, 103, 431-3. https://doi.org/10.1002/ijc.10834
  34. Tarkkonen KM, Nilsson EM, Kahkonen TE, et al (2012). Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One, 7, 49970. https://doi.org/10.1371/journal.pone.0049970
  35. Turner SD, Bush WS (2011). Multivariate analysis of regulatory SNPs: empowering personal genomics by considering cisepistasis and heterogeneity. Pac Symp Biocomput, 276-87.
  36. Zhang J, Qiu LX, Wang ZH, et al (2010a). Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 124, 419-24. https://doi.org/10.1007/s10549-010-0846-7
  37. Zhang YX, Wang XM, Kang S, et al (2013). Common variants in the PALB2 gene confer susceptibility to breast cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 7149-54. https://doi.org/10.7314/APJCP.2013.14.12.7149
  38. Zhang Z, Wang M, Wu D, et al (2010b). P53 codon 72 polymorphism contributes to breast cancer risk: a metaanalysis based on 39 case-control studies. Breast Cancer Res Treat, 120, 509-17. https://doi.org/10.1007/s10549-009-0480-4
  39. Zhuo W, Zhang Y, Xiang Z, et al (2009). Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res, 28, 115. https://doi.org/10.1186/1756-9966-28-115

Cited by

  1. 14-bp Insertion/Deletion Polymorphism of the HLA-G gene in Breast Cancer among Women from North Western Iran vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6155
  2. Association of p53 rs1042522, MDM2 rs2279744 and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population vol.5, pp.1, 2015, https://doi.org/10.1038/srep13300
  3. Genetic variants in FGFR2 and TNRC9 genes are associated with breast cancer risk in Pakistani women vol.14, pp.4, 2016, https://doi.org/10.3892/mmr.2016.5633
  4. “p53 Polymorphism at Codon 72 and Breast Cancer” - Letter vol.22, pp.1, 2017, https://doi.org/10.15430/JCP.2017.22.1.55